AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Morphic Holding Inc

Healthcare US MORF

35.735USD
0.26(0.72%)

Last update at 2024-02-22T20:54:00Z

Day Range

34.8136.11
LowHigh

52 Week Range

19.3463.08
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -58.97400M -95.54200M -45.56900M -42.41600M -23.83100M
Minority interest - - - - -
Net income -59.04100M -94.24000M -44.99900M -43.32800M -23.83100M
Selling general administrative 32.14M 27.81M 18.50M 10.23M 5.36M
Selling and marketing expenses - - - - -
Gross profit 70.81M 19.79M 44.95M 16.98M 3.36M
Reconciled depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Ebit -64.40100M -96.83600M -48.30600M -46.98800M -24.62800M
Ebitda -63.39600M -95.80600M -47.18000M -46.16700M -24.08900M
Depreciation and amortization 1.00M 1.03M 1.13M 0.82M 0.54M
Non operating income net other - - 1.61M - -
Operating income -63.39600M -95.80600M -47.18000M -46.98800M -24.62800M
Other operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Interest expense 4.57M 0.27M 2.74M 4.57M 0.00000M
Tax provision 0.07M 0.00000M -0.57000M 0.91M 0.00000M
Interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Net interest income 4.57M 0.27M 1.63M 4.67M 0.87M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M -1.30200M -0.57000M 0.91M 0.80M
Total revenue 70.81M 19.79M 44.95M 16.98M 3.36M
Total operating expenses 134.20M 115.60M 92.12M 63.97M 27.99M
Cost of revenue - - - 53.73M 22.63M
Total other income expense net 4.42M 0.26M 1.61M 4.57M -0.07400M
Discontinued operations - - - - -
Net income from continuing ops -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Net income applicable to common shares -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 368.59M 426.29M 242.38M 247.44M 189.31M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.93M 10.20M 11.17M 3.09M 1.22M
Total liab 19.47M 89.59M 97.19M 106.52M 241.86M
Total stockholder equity 349.12M 336.70M 145.20M 140.92M -52.55200M
Deferred long term liab - - 57.75M - -
Other current liab 11.69M 11.63M 39.44M 6.73M 3.30M
Common stock 0.00400M 0.00400M 0.00300M 0.00300M 0.00100M
Capital stock 0.00400M 0.00400M 0.00300M 0.00300M 0.00000M
Retained earnings -297.09500M -238.05400M -142.51200M -97.51300M -54.18500M
Other liab - 51.33M 57.75M 71.17M 67.14M
Good will - - - - -
Other assets 0.77M 7.96M 0.34M 0.42M 0.34M
Cash 59.27M 408.13M 228.26M 101.56M 185.90M
Cash and equivalents - - - - -
Total current liabilities 17.13M 38.26M 39.44M 35.35M 34.90M
Current deferred revenue 0.47M 20.63M 25.27M 23.45M 29.86M
Net debt -55.43400M -403.08600M -228.26400M -101.55900M -185.90100M
Short term debt 1.49M 1.21M -29.11100M - -
Short long term debt - - - - -
Short long term debt total 3.84M 5.05M - - -
Other stockholder equity 649.55M 575.23M 287.73M -9.05100M 2.84M
Property plant equipment 5.63M 7.39M 2.61M 3.45M 1.84M
Total current assets 362.18M 418.33M 239.44M 243.57M 187.12M
Long term investments - - - - -
Net tangible assets 349.12M 336.70M 145.20M 140.92M -52.55200M
Short term investments 288.98M 236.70M 126.22M 135.46M 0.00000M
Net receivables 0.46M 2.31M 7.31M 3.47M 0.00000M
Long term debt - - - - -
Inventory -0.45500M -2.30700M -7.31400M - -
Accounts payable 3.48M 4.80M 3.85M 5.17M 1.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.33900M -0.48200M -0.02100M 0.04M -1.21000M
Additional paid in capital - - - - -
Common stock total equity - - 0.00300M 0.00300M -
Preferred stock total equity - - - - -
Retained earnings total equity - - -142.51200M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.77M 0.57M 0.34M 0.42M 0.34M
Deferred long term asset charges - - - - -
Non current assets total 6.41M 7.96M 2.95M 3.86M 2.18M
Capital lease obligations 3.84M 5.05M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -56.45100M -112.16000M 8.72M -135.98600M -0.65600M
Change to liabilities -69.20000M -13.85100M -9.01600M 0.93M 97.50M
Total cashflows from investing activities -56.45100M -113.18000M 8.18M -135.98600M -0.65600M
Net borrowings - - - - -0.65200M
Total cash from financing activities 45.27M 266.31M 38.30M 93.30M 89.47M
Change to operating activities -5.59500M -2.50800M 2.76M 1.35M 1.05M
Net income -59.04100M -95.54200M -44.99900M -43.32800M -23.83100M
Change in cash -112.16200M 69.67M 0.49M -84.34200M 165.15M
Begin period cash flow 171.99M 102.32M 101.83M 186.18M 21.02M
End period cash flow 59.83M 171.99M 102.32M 101.83M 186.18M
Total cash from operating activities -100.97700M -83.46100M -45.99000M -41.65100M 76.34M
Issuance of capital stock 39.21M 265.22M 33.65M 93.27M 90.12M
Depreciation 1.00M 1.03M 1.13M 0.82M 0.54M
Other cashflows from investing activities - - - -133.82800M 0.00300M
Dividends paid - - - - -
Change to inventory - -2.50800M 2.83M 1.41M -
Change to account receivables 1.85M 5.01M -3.84700M -3.46700M -3.46700M
Sale purchase of stock 0.89M 1.09M 1.11M 93.30M 90.12M
Other cashflows from financing activities 5.17M -113.18000M 3.53M 0.03M 90.12M
Change to netincome 30.00M 22.40M 11.05M 2.04M 1.07M
Capital expenditures 0.36M 1.02M 0.54M 2.16M 0.66M
Change receivables - - -3.84700M - -
Cash flows other operating - - -0.75700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 0.49M - -
Change in working capital -72.94300M -11.35200M -13.62000M -1.18700M 98.56M
Stock based compensation 29.05M 21.18M 11.05M 3.53M 1.00M
Other non cash items 0.95M 1.22M 0.45M -0.02200M 0.04M
Free cash flow -101.34200M -84.48100M -46.53400M -43.80900M 75.68M

Fundamentals

  • Previous Close 35.48
  • Market Cap1437.57M
  • Volume466473
  • P/E Ratio-
  • Dividend Yield0.0%
  • EBITDA-154.78200M
  • Revenue TTM6.66M
  • Revenue Per Share TTM0.16
  • Gross Profit TTM -31.25400M
  • Diluted EPS TTM-3.29

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MORF
Morphic Holding Inc
0.26 0.72% 35.73 0.0 0.0 208.43 1.92 99.98 -4.2995
NVO
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

Profile

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Morphic Holding Inc

35 Gatehouse Drive, A2, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Dr. Praveen P. Tipirneni M.D. CEO, MD & Director 1968
Dr. Bruce N. Rogers Ph.D. Pres 1969
Dr. Timothy A. Springer Ph.D. Founder, Independent Director & Member of Scientific Advisory Board 1948
Dr. Marc Schegerin M.B.A., M.D. CFO & COO 1976
Mr. William D. DeVaul Esq. Gen. Counsel & Sec. 1971
Mr. Robert E. Farrell Jr., CPA, CPA Sr. VP of Fin. & Operations and Chief Accounting Officer 1965
Dr. Blaise Lippa Ph.D. Chief Scientific Officer NA
Mr. Aaron Pelta Sr. VP of Bus. & Corp. Devel. NA
Ms. Joanne Gibbons Sr. VP of Regulatory Affairs NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).